Author:
Frederich Robert,McNeill Robert,Berglind Niklas,Fleming Douglas,Chen Roland
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference21 articles.
1. Khoo J, Rayner CK, Jones KL, Horowitz M: Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag. 2009, 5: 683-698.
2. Onglyza® (saxagliptin): Full Prescribing Information. 2009, Princeton, NJ/Wilmington, DE: Bristol-Myers Sqibb/AstraZeneca Pharmaceuticals LP
3. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R: Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin . 2006, 25: 2401-11.
4. DeFronzo R, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, Chen R: Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes. 2009, 58: 547-P
5. Chacra AR, Tan GH, Ravichandran S, List J, Chen R, CV181-040 Investigators: Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011, 8: 150-159. 10.1177/1479164111404574.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献